Erratum: Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5 (Journal of Clinical Oncology (2018) DOI: 10.1200/JCO.2017.76.4258);Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5

Journal of Clinical Oncology

Volumn 36, Issue 19, 2018, Pages 1941-1948

  Dowsett, Mitch ^a,b   Sestak, Ivana ^c   Regan, Meredith M ^d   Dodson, Andrew ^a   Viale, Giuseppe ^e,f   Thurlimann, Beat ^g,h   Colleoni, Marco ^f   Cuzick, Jack ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MILAN   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CONTROLLED STUDY; DISTANT METASTASIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HIGH RISK POPULATION; HUMAN; INTERMEDIATE RISK POPULATION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; BIOSYNTHESIS; BREAST TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; RISK; STATISTICAL MODEL; TUMOR RECURRENCE;

AGED; ANASTROZOLE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RISK; TAMOXIFEN;

EID: 85049661377     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.20.00023     Document Type: Erratum

References (34)

1. Goss PE, Ingle JN, Pritchard KI, et al: Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209-219, 2016
2. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816, 2013
3. Mamounas E, Bandos H, Lembersky BC, et al: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42. Cancer Res 77, 2017 (suppl 4; abstr S1-05)
4. Blok EJ, Kroep JR, Kranenbarg EM-K, et al: Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05). J Natl Cancer Inst 110:djx134, 2018
5. Gray RG, Rea D, Handley K, et al: ATTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 5)
6. Cuzick J, Dowsett M, Pineda S, et al: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29: 4273-4278, 2011
7. Sestak I, Dowsett M, Zabaglo L, et al: Factors predicting late recurrence for estrogen receptorpositive breast cancer. J Natl Cancer Inst 105: 1504-1511, 2013
8. Mittempergher L, Saghatchian M, Wolf DM, et al: A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. Mol Oncol 7:987-999, 2013
9. Pan H, Gray R, Braybrooke JP, et al: 20-year recurrence risks for patients with estrogen receptorpositive breast cancer after adjuvant endocrine treatment for only 5 years. N Engl J Med 377:1836-1846, 2017
10. Cuzick J, Sestak I, Baum M, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141, 2010
11. Regan MM, Neven P, Giobbie-Hurder A, et al: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101-1108, 2011
12. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combinationwith tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002
13. Colleoni M, Giobbie-Hurder A, Regan MM, et al: Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 29:1117-1124, 2011
14. Van Houwelingen JC, Le Cessie S: Predictive value of statistical models. Stat Med 9:1303-1325, 1990
15. American Cancer Society: Cancer Facts and Figures 2017. Atlanta, GA, American Cancer Society, 2017
16. Goss PE, Ingle JN, Pater JL, et al: Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26: 1948-1955, 2008
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level metaanalysis of the randomised trials. Lancet 386: 1341-1352, 2015
18. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
19. Dowsett M, Sestak I, Lopez-Knowles E, et al: Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31: 2783-2790, 2013
20. Buus R, Sestak I, Kronenwett R, et al: Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108:djw149, 2016
21. Sgroi DC, Sestak I, Cuzick J, et al: Prediction of late distant recurrence in patients with oestrogenreceptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the Trans-ATAC study population. Lancet Oncol 14:1067-1076, 2013
22. Massagué J: Sorting out breast-cancer gene signatures. N Engl J Med 356:294-297, 2007
23. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
24. Nielsen TO, Parker JS, Leung S, et al: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222-5232, 2010
25. Sgroi DC, Carney E, Zarrella E, et al: Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 105:1036-1042, 2013
26. Zhang Y, Schnabel CA, Schroeder BE, et al: Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 19: 4196-4205, 2013
27. Dubsky P, Brase JC, Jakesz R, et al: The EndoPredict score identifies late distant metastases in ER+/HER22 breast cancer patients. Brit J Cancer 109:2959-2964, 2013
28. Filipits M, Rudas M, Jakesz R, et al: A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17:6012-6020, 2011
29. Cardoso F, van't Veer LJ, Bogaerts J, et al: 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375: 717-729, 2016
30. Harris LN, Ismaila N, McShane LM, et al: Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34:1134-1150, 2016
31. Duffy MJ, Harbeck N, NapM, et al: Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 75:284-298, 2017
32. Coates AS, Winer EP, Goldhirsch A, et al: Tailoring therapies: Improving the management of early breast cancer-St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533-1546, 2015
33. Senkus E, Kyriakides S, Ohno S, et al: Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26: V8-v30, 2015 (suppl 5)
34. Sestak I, Buus R, Cuzick J, et al: Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer. A secondary analysis of a randomised trial. JAMA Oncol. 10.1001/jamaoncol.2017.5524 [Epub ahead of print]